Johnson & Johnson (JNJ)
(Real Time Quote from BATS)
$162.32 USD
-0.90 (-0.55%)
Updated Sep 24, 2024 02:20 PM ET
4-Sell of 5 4
C Value F Growth D Momentum D VGM
Price, Consensus and EPS Surprise
JNJ 162.32 -0.90(-0.55%)
Will JNJ be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for JNJ based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for JNJ
J&J Seeks 3rd Talc-Related Bankruptcy: Time to Sell the Stock?
Johnson & Johnson Files for Bankruptcy Over Talc Lawsuits for the Third Time
JNJ: What are Zacks experts saying now?
Zacks Private Portfolio Services
Sanofi's Sarclisa Gets FDA Nod for Expanded Use in Multiple Myeloma
Pharma Stock Roundup: FDA Approvals for LLY, MRK, AZN & JNJ Drugs
J&J's Rybrevant Receives FDA Nod for Expanded Use in NSCLC
Other News for JNJ
Johnson & Johnson: Wait For More Clarity (Rating Downgrade)
J&J unit third bankruptcy attempt location to be determined by Texas judge
Analysts agree that Kenvue's Neutrogena needs a face-lift
NEW YORK MARKET CLOSE: Shares up as US private sector growth mixed
IN BRIEF: J&J says daratumumab gets positive CHMP opinion for myeloma